Cingulate (CING) Assets Average (2022 - 2026)
Cingulate's (CING) quarterly Assets Average came in at $12.8 million in Q4 2025, down 10.03% YoY from $14.2 million in Q4 2024, and down 6.37% on a QoQ basis from $13.7 million in Q1 2025.
Cingulate (CING) Assets Average (2022 - 2026) Analysis & Trends
Cingulate (CING) has 4 years of Assets Average data on file, last reported at $12.8 million in Q4 2025.
- Quarterly Assets Average fell 10.03% year-over-year to $12.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.8 million (down 10.03% YoY) and the FY2025 annual result came in at $15.0 million, up 63.1% from the prior year.
- Assets Average retreated to $12.8 million in Q4 2025, from $13.7 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $20.7 million in Q1 2022 to a low of $4.5 million in Q1 2024.
- A 4-year average of $10.7 million and a median of $11.1 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average tumbled 65.04% — and 2025, when it jumped 204.19%.
- Tracing CING's Assets Average over 4 years: stood at $13.4 million in 2022, then plunged by 65.04% to $4.7 million in 2023, then surged by 203.84% to $14.2 million in 2024, then decreased by 10.03% to $12.8 million in 2025.
- The last three Assets Average figures came in at $12.8 million (Q4 2025), $13.7 million (Q1 2025), and $14.2 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 19.82 Bn |
| 10 | Cingulate | 72.26 Mn | 72.26 Mn | - | 24.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.07 Mn |
| Dec 31, 2025 | 12.80 Mn |
| Mar 31, 2025 | 13.67 Mn |
| Dec 31, 2024 | 14.22 Mn |
| Sep 30, 2024 | 9.35 Mn |
| Jun 30, 2024 | 5.31 Mn |
| Mar 31, 2024 | 4.49 Mn |
| Dec 31, 2023 | 4.68 Mn |
| Sep 30, 2023 | 5.55 Mn |
| Jun 30, 2023 | 6.20 Mn |
| Mar 31, 2023 | 9.28 Mn |
| Dec 31, 2022 | 13.39 Mn |
| Sep 30, 2022 | 14.59 Mn |
| Jun 30, 2022 | 16.12 Mn |
| Mar 31, 2022 | 20.66 Mn |